Emzor Pharmaceutical Industries Limited — Companies

Why it is on record

Largest wholly indigenous Nigerian pharmaceutical manufacturer by output; founded by Dr Stella Okoli, OON — one of the earliest women industrialists of the post-Independence era. Operates one of the few Nigerian plants WHO-prequalified for sub-Saharan Africa antimalarial supply.

Record held

Largest indigenous Nigerian pharmaceutical manufacturer; one of three African plants WHO-prequalified for artemether-lumefantrine.

Founders

Dr Stella Chinyelu Okoli, OON (b. 1944, Kano; pharmacy graduate of University of Bradford and Loughborough).

Headquarters

Aswani Industrial Estate, Isolo, Lagos.

Lineage / corporate history

Emzor Chemists Limited founded 1977 by Stella Okoli as a retail pharmacy at Aswani, Lagos; manufacturing arm Emzor Pharmaceutical Industries Limited incorporated 1984; flagship product Emzor Paracetamol launched late 1980s; expanded into antimalarials (Emzoquin, Emzor Lumartem), antibiotics and antiretrovirals through the 1990s and 2000s.

Current leadership

Group Chairman: Dr Stella Okoli, OON. Managing Director: Uzoma Ezeoke.

Key dates

1977Stella Okoli opens Emzor Chemists at Aswani, Lagos.
1984Emzor Pharmaceutical Industries Limited incorporated as manufacturing arm.
Late 1980sLaunches Emzor Paracetamol — becomes the most distributed branded paracetamol in Nigeria.
2014Becomes one of three African plants WHO-prequalified for artemether-lumefantrine (antimalarial).
2023Breaks ground on $150m active-pharmaceutical-ingredient (API) plant at Sagamu, Ogun State — first integrated API facility in West Africa.

Deep dive

Emzor is the largest wholly indigenous Nigerian pharmaceutical manufacturer and one of the most consequential industrial enterprises founded by a Nigerian woman. Dr Stella Okoli — a Bradford- and Loughborough-trained pharmacist — opened the first Emzor Chemists at Aswani, Lagos in 1977, capitalising the manufacturing arm seven years later as Emzor Pharmaceutical Industries Limited. The flagship Emzor Paracetamol, launched in the late 1980s, became the most distributed branded paracetamol in the Nigerian retail market and remains the foundation of the company's revenue.

The expansion into antimalarials through the 2000s and 2010s positioned Emzor as one of three African manufacturers prequalified by the World Health Organization for artemether-lumefantrine supply to the Global Fund and PMI procurement channels. This qualification, achieved at the Sagamu (Ogun State) plant in 2014, made Emzor one of a small number of African pharmaceutical firms eligible to bid for tenders under WHO/UNICEF/Global Fund rules.

The May 2018 BBC Africa Eye documentary 'Sweet Sweet Codeine', which traced codeine-based cough syrup diversion to abuse markets in Northern Nigeria, named Emzor and Bioraj as two of the manufacturers whose products had been diverted. NAFDAC suspended codeine-syrup production at both plants within days; Emzor maintained that diversion had occurred downstream of its distribution chain and the suspension was lifted on production-line audit. The episode remains the most prominent public-health controversy involving a Nigerian pharmaceutical manufacturer.

The $150m API plant at Sagamu — under construction since 2023 — will be the first integrated active-pharmaceutical-ingredient facility in West Africa. Active pharmaceutical ingredient manufacturing has been the missing layer in Nigerian pharmaceutical industrial policy since the 1990s; the Sagamu API plant, if commissioned on schedule, would reduce the country's near-total dependence on Indian and Chinese API imports for finished-dose manufacturing.

Controversies & accountability

· 2018 BBC Africa Eye investigation 'Sweet Sweet Codeine' documented diversion of Emzor codeine-based cough syrup into the illicit market in Northern Nigeria; Emzor and Bioraj jointly suspended production of codeine syrup at NAFDAC's directive in May 2018.